References

Halki Diabetes Remedy

Reverse Your Diabetes Naturally

Get Instant Access

1. Banting, F.G. et al. (1922). The internal secretion of the pancreas. American Journal of Physiology, 59, 479.

2. Banting, F.G. and Best, C.H. (1922). The internal secretion of the pancreas. Journal of Laboratory and Clinical Medicine, 7, 251-266.

3. Bliss, M. (1996). The discovery of insulin. 75th Anniversary Edition. McClelland and Stewart, Inc., Toronto 11.

4. Bliss, M. (1993). The history of insulin. Diabetes Care, 16(Suppl. 3), 4-7.

5. Sherwin, R.S. (1996). Diabetes Mellitus. In: Bennett, J.C. and Plum, F. (eds.) Cecil Textbook of Medicine, 20th ed. W.B. Saunders Company, Philadelphia, p. 1265.

6. Chance, R.E. and Frank, B.H. (1993). Research, development, production, and safety of biosynthetic human insulin. Diabetes Care, 16(Suppl. 3), 133-142.

7. Galloway, J.A. and Chance, R.E. (1994). Improving insulin therapy: achievements and challenges. Hormone And Metabolic Research, 26(12), 591-598.

8. Brange, J. et al. (1990). Monomeric insulins and their experimental and clinical implications. Diabetes Care, 13(9), 923-954.

9. The Diabetes Control and Complications Trial Research Group (DCCT). (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329, 977-986.

10. Reichard, P. et al. (1993). The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. The New England Journal of Medicine, 329, 304-309.

11. Ohkubo, Y. et al. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice, 28(2), 103-117.

12. JDFI World Conference on Diabetes Research. (1985). Current Status, Future Directions. Report of the Juvenile Diabetes Foundation International World Conference on Diabetes Research (Nov2-6, Monaco), p. 42.

13. Schlichtkrull, J. et al. (1974). Monocomponent insulin and its clinical implications. Hormone and Metabolic Research, (Suppl. Ser)5, 134-143.

14. Chance, R.E. et al. (1976). The immunogenicity of insulin preparations. Acta Endocrinologica, 83(Suppl. 205), 185-196.

15. Hall, S.S. (1988). Invisible Frontiers. The race to synthesise a human gene. Sidgwick and Jackson Limited, London.

16. Beckman, A.O. and Roberts, E. (1988). Genetically Engineered Insulin Videotape. National Academy of Sciences and Beckman Research Institute of the City of Hope December I, 1988. Copy of the videotaped proceedings available through the History of Medicine Division of the National Library of Medicine, Bethesda MD and can be obtained via interlibrary loan per personal communication with John Parascandola, Chief, History of Medicine Division.

17. Goeddel, D.V. et al. (1979). Expression in Escherichia coli of chemically synthesized genes for human insulin. Proceedings of the National Academy of Sciences of the United States of America, 76(1), 106-110.

18. Itakura, K. et al. (1977). Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science, 198, 1056-1063.

19. Itakura, K. and Riggs, A.D. (1980). Chemical DNA synthesis and recombinant DNA studies. Science, 209, 1401-1405.

20. Itakura, K. et al. (1984). Synthesis and use of synthetic oligonucleotides. Annual Review of Biochemistry, 53, 323-356.

21. Riggs, A.D. et al. (1980). Synthesis, cloning, and expression ofhormone genes in Escherichia coli. Recent Progress in Hormone Research, 36, 261-276.

22. Crea, R. et al. (1978). Chemical synthesis of genes for human insulin. Proceedings of the National Academy of Sciences of the United States of America, 75(12), 5765-5769.

23. Johnson, I.S. (1983). Human insulin from recombinant DNA technology. Science, 219, 632-637.

24. Frank, B.H. et al. (1981). The production of human proinsulin and its transformation to human insulin and C-peptide. In: Rich, D.H. and Gross, E. (eds.) PEPTIDES: Synthesis-Structure-Function. Proceedings of the Seventh American Peptide Symposium. Pierce Chemical Company, Rockford. pp. 729-738.

25. Galloway, J. A. et al. (1992). Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal, and human pharmacology studies, and clinical trial experience. Diabetes Care, 15(5), 666-692.

26. DiMarchi, R. et al. (1989). Synthesis of insulin-like growth factor I through recombinant DNA techniques and selective chemical cleavage at tryptophan. In: Tam, J.P. and Kaiser, E.T. (eds.) Synthetic Peptides: Approaches to Biological Problems. Alan R Liss, Inc., New York. pp. 283-294.

27. Furman, T C. et al. (1987). Recombinant human insulin-like growth factor II expressed in Escherichia coli. Biotechnology, 5, 1047-1051.

28. Chance, R.E. et al. (1981). The production of human insulin using recombinant DNA technology and a new chain combination procedure. In: Rich, D.H. and Gross, E. (eds.) PEPTIDES: Synthesis-Structure-Function. Proceedings of the Seventh American Peptide Symposium. Pierce Chemical Company, Rockford. pp. 721-728.

29. Blundell, T. et al. (1972). Insulin: the structure in the crystal and its reflection in chemistry and biology. Advances in Protein Chemistry, 26, 279-402.

30. Baker, E.N. et al. (1988). The structure of 2Zn pig insulin crystals at 1.5 Ä resolution. Philosophical Transactions Of The Royal Society Of London. B: Biological Sciences, 319(1195), 369-456.

31. Mosekilde, E. et al. (1989). Modeling absorption kinetics of subcutaneous injected soluble insulin. Journal of Pharmacokinetics and Biopharmaceutics, 17(1), 67-87.

32. Chance, R.E. et al. (1998). Discovery and development of insulin lispro. Drugs of Today, 34(Suppl. C), 1-9.

33. Brems, D.N. et al. (1992). Altering the association properties of insulin by amino acid replacement. Protein Engineering, 5(6), 527-533.

34. DiMarchi, R.D. et al. (1992). Synthesis of a fast-acting insulin based on structural homology with insulin-like growth factor I. In: Smith, J A. and Rivier, J.E. (eds.) Peptides. Chemistry and Biology. Proceedings of the Twelfth American Peptide Symposium, ESCOM, Leiden, pp. 26-28.

35. DiMarchi, R.D. et al. (1994). Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Hormone Research, 41(Suppl. 2), 93-96.

36. Long, H.B. et al. (1992). Human insulin analogs with rapid onset and short duration of action. In: Smith, J. A. and Rivier, J.E. (eds.). Peptides. Chemistry and Biology. Proceedings of the Twelfth American Peptide Symposium. ESCOM, Leiden, pp. 88-90.

37. Frank, B.H. et al. (1991). Manipulation of the position of proline in the B-chain produces monomeric insulins. Diabetes, 40(Suppl. 1), 423A.

38. Chance, R.E. et al. (1996). Insulin analogs modified at position 29 of the B chain. United States Patent Number 5,514,646. May 7, 1996.

39. Slieker, L. J. et al. (1997). Modifications in the BIO and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia, 40(Suppl. 2), S54-S61.

40. Shaw, W.N. and Su, K.S.E. (1991). Biological aspects of a new human insulin analog: [Lys(B28), Pro(B29)]-human insulin. Diabetes, 40(Suppl. 1), 464A.

41. Galloway, J. A. et al. (1991). Human insulin and its modifications. In: Reidenberg, M. M. (ed). The clinical pharmacology of biotechnology products. Elsevier, Amsterdam, pp. 23-34.

42. Su, K.S. et al. (1994). Using dog model for comparing time action of insulins after subcutaneous (s.c.) injection: prediction of rapid onset of a new insulin analog [Lys(B28), Pro(B29)]-human insulin (KP). Pharmaceutical Research, ll(10)(Suppl.), S3 5 7.

43. Bakaysa, D.L. et al. (1996). Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex. Protein Science, 5(12), 2521-2531.

44. Radziuk, J. et al. (1997). Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs—LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin—assessed in a conscious pig model. Diabetes, 46, 548-556.

45. USAN Council. (1995). New Names. Clinical Pharmacology and Therapeutics, 57, 98.

46. Hua, Q. -X. et al. (1996). Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue. Journal of Molecular Biology, 264, 390-403.

47. Ciszak, E. et al. (1995). Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB2'-human insulin. Structure, 3, 615-622.

48. Birnbaum, D.T. et al. (1997). Assembly and dissociation of human insulin and LysB28ProB29-insulin hexamers: a comparison study. Pharmaceutical Research, 14(1), 25-36.

49. Frank, B.H. et al. (1995). LysB28ProB29-human insulin (insulin lispro): solution properties of a rapid-acting insulin. Diabetologia, 38(Suppl. 1), A189.

50. Chance, R.E. et al. (1981). Chemical, physical, and biological properties of recombinant human insulin. In: Gueriguian, J L. (ed.). Insulins, Growth Hormone, and Recombinant DNA Technology. Raven Press, New York. pp. 71-86.

51. Chance, R.E. et al. (1981). Chemical, physical, and biologic properties of biosynthetic human insulin. Diabetes Care, 4(2), 147-154.

52. Johnson, I.S. (1982). Authenticity and purity of human insulin (recombinant DNA). Diabetes Care, 5(Suppl. 2), 4-12.

53. Frank, B.H. and Chance, R.E. (1983). Two routes for producing human insulin utilizing recombinant DNA technology. Münch med Wschr, 125(Suppl. 1), S14-S20.

54. Frank, B.H. and Chance, R.E. (1986). The preparation and characterization of human insulin of recombinant DNA origin. In: Joyeaux, A., Leygue, G., Morre, M., Roncucci, R. and Schmelck, P.H. (eds.). Therapeutic Agents Produced by Genetic Engineering Quo Vadis? Symposium, Sanofi Group. Toulouse-Labege. Sanofi Recherche, Montpellier, pp. 137-146.

55. Prouty, W.F. (1991). Production-scale purification processes. In: Chiu, Y-y. H. and Gueriguian, J.L. (eds.). Drug Biotechnology Regulation. Scientific Basis and Practices. Marcel Dekker, Inc., New York. pp. 221-262.

56. KroefF, E.P. et al. (1989). Production scale purification of biosynthetic human insulin by reversed-phase high-performance liquid chromatography. Journal of Chromatography, 461, 45-61.

57. Slieker, L.J. et al. (1994). Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics. In: LeRoith, D. and Raizada, M.K., (eds.). Current Directions in Insulin-Like Growth Factor Research. Plenum Press, New York. pp. 2532.

58. Atkins, L.M. et al. (1987). Recommendations for establishment of reference standards for recombinant-DNA-derived proteins and polypeptides. Journal Association of Official Analytical Chemists, 70(4), 610-617.

59. Farid, N. A. et al. (1989). Liquid chromatographic control of the identity, purity and "potency" of biomolecules used as drugs. Journal of Pharmaceutical and Biomedical Analysis, 7(2), 185-188.

60. Kroeff, E.P. and Chance, R.E. (1982). Applications of high-performance liquid chromatography for analysis of insulins. In: Gueriguian, J.L., Bransome, E.D., Jr. and Outschoorn, A.S. (Workshop Organizers) (eds.). Hormone Drugs. Proceedings of the FDA-USP Workshop on Drug and Reference Standards for Insulins, Somatropins, and Thyroid-axis Hormones. United States Pharmacopeial Convention, Inc., Rockville. pp. 148-162.

61. Weiss, M. A. et al. (1991). Heteronuclear 2D NMR studies of an engineered insulin monomer: assignment and characterization of the receptor-binding surface by selective 2H and 13C labeling with application to protein design. Biochemistry, 30, 7373-7389.

62. Riggin, A. et al. (1997). A non-isotopic probe-hybridization assay for residual DNA in biopharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis, 16(4), 561572.

63. Slieker, L.J. and Sundell, K. (1991). Modifications in the 28-29 position of the insulin B-chain alter binding to the IGF-I receptor with minimal effect on insulin receptor binding. Diabetes, 40(Suppl. 1), 168A.

64. Slieker, L.J. et al. (1993). Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics. In: Du, Y-C., Tam, J.P. and Zhang, Y-S. (eds.). Peptides-Biology and Chemistry. Proceedings of the 1992 Chinese Peptide Symposium. ESCOM, Leiden, pp. 7-10.

65. Schwartz, G.P. et al. (1987). A superactive insulin [BlO-aspartic acid] insulin (human). Proceedings of the National Academy of Sciences of the United States of America, 84, 6408-6411.

66. Drejer, K. (1992). The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes/Metabolism Reviews, 8(3), 259-286.

67. Dideriksen, L.H. et al. Carcinogenic effect on female rats after 12 months administration of insulin analogue BIO Asp. Diabetes, 41(Suppl. 1), 143 A.

68. J0rgensen, L.N. et al. (1992). Carcinogenic effect of the human insulin analogue BIO Asp in female rats. Diabetologia, 35(Suppl. 1), A3.

69. Jargensen, L.N. and Dideriksen, L.H. (1993). Preclinical studies of rapid-acting insulin analogues. In: Berger, M. and Gries, F.A. (eds.). Frontiers in insulin pharmacology. Thieme Medical Publishers, Inc., New York. pp. 110-117.

70. DeMeyts, P. et al. (1993). Enhanced mitogenic potency of insulin analogues in a cell line devoid of IGF-I receptors correlates with slow dissociation from insulin receptors. Diabetes, 42(Suppl. 1), 163A.

71. DeMeyts, P. (1994). The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia, 37(Suppl. 2), S135-S148.

72. Danielsen, G. et al. (1995). Early signalling events of insulin analogs. European Journal of Endocrinology, 132(Suppl. 1), 8.

73. Lundemose, A.G. et al. (1995). Molecular actions of insulin analogues. In: Baba, S., Kaneko, T. (Eds.) Diabetes, 1994. Elsevier Science BV, Amsterdam 469-472.

74. Hansen, B.F. et al. (1996). Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochemical Journal, 315, 271-279.

75. Liu, L. et al. (1997). IGF-I receptor-mediated signalling of the human insulin analogue HOE 901. Diabetologi,a 40(Suppl. 1), A355.

76. Berti, L. et al. (1998). The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to ASP(BIO) and regular insulin. Hormone and Metabolic Research, 30, 123-129.

77. Llewelyn, J. et al. (1998). Preclinical studies on insulin lispro. Drugs of Today, 34(Suppl. C), 11-21.

78. Drejer, K. et al. (1991). Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes, 40, 1488-1495.

79. Hamel, F.G. et al. (1997). BlO-Asp insulin (B10), but not B28-Lys, B29-Pro insulin (LYSPRO), is resistant to metabolism by hepatocytes and insulin degrading enzyme (IDE). Diabetes, 46(Suppl. 1), 204A.

80. Somwar, R. et al. (1998). Stimulation of glucose and amino acid transport and activation of the insulin signalling pathways by insulin lispro in L6 skeletal muscle cells. Clinical Therapeutics, 20(1), 125-140.

81. Slieker, L.J. and Sundell, K.L. (1994). In vitro analysis of Lys(B28), Pro(B29) human insulin (LY275585): comparison to human insulin in terms of insulin and IGF-I receptor binding, glucose uptake into adipocytes and thymidine incorporation into smooth muscle cells. Unpublished report on file Lilly Research Laboratories, Preclinical Pharmacology Report No. 7.

82. Fawcett, J. et al. (1998). Effect of insulin analogs on DNA synthesis in cultured rat liver cells. Diabetes, 47(Suppl. 1), A410.

83. Lilly Research Laboratories. Data on file.

84. Helton, D.R. et al. (1996). General pharmacology of insulin lispro in animals. Arzneimittel-Forschung/Drug Research, 46(1), 91-97.

85. Zimmermann, J. (1994). Subchronic and chronic toxicity, and mutagenicity studies conducted with LysPro [Lys(B28), Pro(B29)] human insulin analog, LY275585. Fifteenth International Diabetes Federation Congress (Nov 6-11, Kobe, Japan), p. 123.

86. Zimmermann, J. (1994). A 12-month chronic toxicity study of LY275585 (human insulin analog) administered subcutaneously to Fischer 344 rats. Diabetes, 43(Suppl. 1), 166 A.

87. Zimmermann, J.L. and Truex, L.L. (1997). 12-month chronic toxicity study of LY275585 (human insulin analog) administered subcutaneously to Fischer 344 rats. International Journal of Toxicology, 16, 639-657.

88. Buelke-Sam, J. et al. (1994). A reproductive and developmental toxicity study in CD rats of LY275585, [Lys(B28), Pro(B29)]-human insulin. Journal of the American College of Toxicology, 13(4), 247-260.

89. Zwickl, C.M. et al. (1995). Immunogenicity of biosynthetic human LysPro insulin compared to native-sequence human and purified porcine insulins in rhesus monkeys immunised over a 6-week period. Arzneimittel-Forschung/Drug Research, 45(1), 524528.

90. Howey, D.C. et al. (1994). [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes, 43, 396-402.

91. Howey, D.C. et al. (1995). [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clinical Pharmacology and Therapeutics 58, 459-469.

92. Heinemann, L. and Woodworth, J. (1998). Pharmacokinetics and glucodynamics of insulin lispro. Drugs of Today, 34(Suppl. C), 23-36.

93. Heinemann, L. et al. (1996). Prandial glycaemia after a carbohydrate-rich meal in type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabetic Medicine, 13, 625-629.

94. Anderson, J.H., Jr. and Koivisto, V.A. (1998). Clinical studies on insulin lispro. Drugs of Today, 34(Suppl. C), 37-50.

95. Anderson, J.H. et al. and the Multicenter Insulin Lispro Study Group. (1997). Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes, 46, 265-270.

96. Anderson, J.H. et al. (1997). Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Archives of Internal Medicine, 157(11), 1249-1255.

97. Anderson, J.H. et al. and the Multicenter Insulin Lispro Study Group.(1997). Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clinical Therapeutics, 19(1), 62-72.

98. Lean, M.E. et al. (1985). Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. British Medical Journa,l 290, 105-108.

99. American Diabetes Association. (1997). Standards of medical care for patients with diabetes mellitus. Diabetes Care, 20(Suppl. 1), S5-S13.

100. Dimitriadis, G.D. and Gerich, J.E. (1983). Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care, 6(4), 374-377.

101. Vignati, L. et al. (1997). Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Clinical Therapeutics, 19(6), 1408-1421.

102. Zinman, B. et al. (1997). Insulin Lispro in CSU Results of a double-blind crossover study. Diabetes, 46, 440-443.

103. Melki, V. et al. (1998). Improvement of HbAic and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care, 21(6), 977-982.

104. Pfutzner, A., Renner, R. and The German Humalog CSE Study Group. (1997). CSH therapy with insulin pumps using insulin lispro. Diabetes, 46(Suppl. 1), 34A.

105. Schmauss, S. et al. (1998). Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin? Diabetic Medicine, 15(3), 247-249.

106. Campbell, R.K. et al. (1998). Impact on clinical status and quality of life of switching from regular insulin to insulin lispro among patients using insulin pumps. The Diabetes Educator, 24(1), 95-99.

107. Schernthaner, G. et al. (1998). Postprandial insulin lispro: a new therapeutic option fortype-1 diabetic patients. Diabetes Care, 21(4), 570-573.

108. Holcombe, J.H. et al. (1998). Comparative study of insulin lispro and regular insulin in prepubertal children with type 1 diabetes. Diabetes, 47(Suppl. 1), A96.

109. Rutledge, K.S. et al. (1997). Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics, 100(6), 968-972.

110. Holcombe, J. et al. (1997). Insulin lispro (LP) results in less nocturnal hypoglycemia compared with regular human insulin in adolescents with type 1 diabetes. Diabetes, 46(Suppl. 1), 103 A.

111. Holcombe, J. et al. (1997). Patient preference for insulin lispro versus Humulin R in adolescents with type 1 diabetes. Diabetologia, 40(Suppl. 1), A343.

112. Holcombe, J. et al. (1997). Comparative study of insulin lispro and regular insulin in 481 adolescents with type 1 diabetes. Diabetologia, 40(Suppl. 1), A344.

113. Rami, B. and Schober, E. (1997). Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. European Journal of Pediatrics, 156, 838-840.

114. Kotsanos, J.G. et al. (1997). Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care, 20(6), 948-958.

115. Desmet, M. et al. (1994). [Lys(B28),Pro(B29)] human insulin (LysPro): patients treated with LysPro versus human regular insulin: quality of life assessment (QOL). Diabetes, 43(Suppl. 1), 167A.

116. Anderson, J.H., Jr. et al. (1996). Insulin analogues: designer insulins with improved characteristics for better patient care. Diabetes News, 17, 5-7.

Was this article helpful?

0 0
Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment